Normalization for body size and population-attributable risk of left ventricular hypertrophy - The strong heart study

被引:197
|
作者
de Simone, G
Kizer, JR
Chinali, M
Roman, MJ
Bella, JN
Best, LG
Lee, ET
Devereux, RB
机构
[1] Cornell Univ, Weill Med Coll, New York, NY 10021 USA
[2] Federico II Univ Hosp, Naples, Italy
[3] Missouri Breaks Ind Res, Timber Lake, SD USA
[4] Univ Oklahoma, Ctr Amer Indian Hlth Res, Oklahoma City, OK USA
基金
美国国家卫生研究院;
关键词
cardiovascular risk; echocardiography; obesity; prognosis; arterial hypertension; risk factors;
D O I
10.1016/j.amjhyper.2004.08.032
中图分类号
R6 [外科学];
学科分类号
1002 ; 100210 ;
摘要
Background: Left ventricular hypertrophy (LVH) is identified by left ventricular mass (LVM) normalized by body surface area (BSA) or height (in meters) also raised to allometric powers. The presence of LVH detected by these indices predicts increased cardiovascular (CV) events. Whether different indexations of LVH differ in their ability to predict excess risk is unknown. Methods: A total of 2400 subjects, (1589 women and 811 men), 59 8 years of age and without prevalent CV disease, valve disease or wall motion abnonnalities and high prevalence of obesity were followed for an average of 86 months. Reference values (mean +/- 1.96 SID) for LVM/ BSA, LVM/BSA(1.5), LVM/m, LVM/m(2.7), and LVM/M-2.13 were obtained in 251 normal participants and population-attributable risk percent (PAR%) for fatal and nonfatal CV events were calculated from prevalence of LVH and hazard ratios (HR). Results: In the entire population or in hypertensive participants, prevalence of LVH was higher for LVM/m(2.7) (20% and 28%) and LVM/m (2.13) (18% and 25%) than for BSA (7% and 11%). Age and sex-adjusted PAR% for LVM/m(2.7) or LVM/m(2.13) were on average 1.8-fold greater than for LVM/BSA in the entire population, and 1.6-fold greater in hypertensive participants, differences that were statistically significant. Conclusions: The presence of LVH identified by LVM normalized for height to allometric powers is associated with a higher proportion of incident CV events than is LVH detected by normalization for BSA and is convenient for identification of individuals at high risk and in need of preventive intervention in populations with high prevalence of obesity. Allometric power methods allow detection of prognostically adverse, obesity-related LVH, which is unidentified using BSA. Am J Hypertens 2005; 18:191-196 (C) 2005 American Journal of Hypertension, Ltd.
引用
收藏
页码:191 / 196
页数:6
相关论文
共 50 条
  • [1] Different normalizations for body size and population attributable risk of left ventricular hypertrophy: The MAVI study
    de Simone, G
    Devereux, RB
    Maggioni, AP
    Gorini, M
    de Divitiis, O
    Verdecchia, P
    AMERICAN JOURNAL OF HYPERTENSION, 2005, 18 (10) : 1288 - 1293
  • [2] Metabolic syndrome and left ventricular hypertrophy in the prediction of cardiovascular events: The Strong Heart Study
    de Simone, G.
    Devereux, R. B.
    Chinali, M.
    Roman, M. J.
    Lee, E. T.
    Resnick, H. E.
    Howard, B. V.
    NUTRITION METABOLISM AND CARDIOVASCULAR DISEASES, 2009, 19 (02) : 98 - 104
  • [3] Association of left ventricular hypertrophy with metabolic risk factors: the HyperGEN study
    de Simone, G
    Palmieri, V
    Bella, JN
    Celentano, A
    Hong, YL
    Oberman, A
    Kitzman, DW
    Hopkins, PN
    Arnett, DK
    Devereux, RB
    JOURNAL OF HYPERTENSION, 2002, 20 (02) : 323 - 331
  • [4] Body size adjustments for left ventricular mass by cardiovascular magnetic resonance and their impact on left ventricular hypertrophy classification
    Brumback, Lyndia C.
    Kronmal, Richard
    Heckbert, Susan R.
    Ni, Hanyu
    Hundley, W. Gregory
    Lima, Joao A.
    Bluemke, David A.
    INTERNATIONAL JOURNAL OF CARDIOVASCULAR IMAGING, 2010, 26 (04) : 459 - 468
  • [5] Body size adjustments for left ventricular mass by cardiovascular magnetic resonance and their impact on left ventricular hypertrophy classification
    Lyndia C. Brumback
    Richard Kronmal
    Susan R. Heckbert
    Hanyu Ni
    W. Gregory Hundley
    João A. Lima
    David A. Bluemke
    The International Journal of Cardiovascular Imaging, 2010, 26 : 459 - 468
  • [6] Prevalence of left ventricular hypertrophy in a general population - The Tromso Study
    Schirmer, H
    Lunde, P
    Rasmussen, K
    EUROPEAN HEART JOURNAL, 1999, 20 (06) : 429 - 438
  • [7] Trajectories of Childhood Blood Pressure and Adult Left Ventricular Hypertrophy: The Bogalusa Heart Study
    Zhang, Tao
    Li, Shengxu
    Bazzano, Lydia
    He, Jiang
    Whelton, Paul
    Chen, Wei
    HYPERTENSION, 2018, 72 (01) : 93 - 101
  • [8] Body build and risk of cardiovascular events in hypertension and left ventricular hypertrophy -: The LIFE (losartan intervention for endpoint reduction in hypertension) study
    de Simone, G
    Wachtell, K
    Palmieri, V
    Hille, DA
    Beevers, G
    Dahlöf, B
    de Faire, U
    Fyhrquist, F
    Ibsen, H
    Julius, S
    Kjeldsen, SE
    Lederballe-Pedersen, O
    Lindholm, LH
    Nieminen, MS
    Omvik, P
    Oparil, S
    Devereux, RB
    CIRCULATION, 2005, 111 (15) : 1924 - 1931
  • [9] Relations of left ventricular mass to fat-free and adipose body mass - The strong heart study
    Bella, JN
    Devereux, RB
    Roman, MJ
    O'Grady, MJ
    Welty, TK
    Lee, ET
    Fabsitz, RR
    Howard, BV
    CIRCULATION, 1998, 98 (23) : 2538 - 2544
  • [10] Left ventricular hypertrophy: Population and molecular genetic study
    Nikitin, YP
    Malyutina, SK
    Dolgikh, MM
    Ryabikov, AN
    Voevoda, MI
    Verevkin, EG
    KARDIOLOGIYA, 1999, 39 (06) : 27 - 32